Income Statement (Annual)

BGB / Blackstone / GSO Strategic Credit Fund Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Cash And Cash Equivalents At Carrying Value 754,744 709,502 831,998 1,412,472 1,837,324 1,837,253 1,992,497
  Cash Held By Funds And Other 724,762 1,404,411 1,045,882 1,808,092 587,132 1,005,161 1,929,531
  Investments 15,128,300 20,847,270 21,729,520 22,765,590 14,324,100 17,694,980 24,434,050
  Accounts Receivable Net 406,140 638,164 888,356 559,321 613,153 772,695 887,162
  Due From Affiliates 860,514 1,120,067 1,192,044 1,128,408 1,240,797 1,442,378 2,028,984
  Finite Lived Intangible Assets Net 595,488 598,535 560,748 458,833 345,547 262,604 409,828
  Goodwill 1,703,602 1,703,602 1,787,392 1,787,392 1,718,519 1,718,519 1,778,192
  Other Assets 337,396 376,372 284,472 338,557 377,189 264,788 242,697
  Deferred Tax Assets Liabilities Net - - - - 1,277,429 1,286,469 725,970
  Assets 21,909,130 28,931,550 29,678,610 31,510,890 22,526,080 26,403,340 34,428,910
Liabilities And Stockholders Equity
  Loans Payable 8,867,568 13,051,400 10,466,500 8,937,638 6,116,747 8,866,366 14,815,440
  Due To Related Parties Current And Noncurrent 1,811,468 2,002,644 1,436,859 1,490,088 1,282,700 1,321,772 937,158
  Employee Related Liabilities Current And Noncurrent 903,260 1,254,978 2,132,939 2,439,257 2,029,918 2,327,762 2,630,019
  Financial Instruments Sold Not Yet Purchased At Fair Value - - - - - - 154,380
  Securities Sold Under Agreements To Repurchase 101,849 142,266 316,352 29,907 40,929 75,324 118,840
  Accounts Payable And Accrued Liabilities Current And Noncurrent 828,873 1,038,888 872,086 1,194,579 648,662 1,081,782 2,043,522
  Liabilities 12,656,840 17,716,600 15,300,940 14,177,350 10,295,620 13,888,400 20,699,360
  Commitments And Contingencies - - - - - - -
  Redeemable Noncontrolling Interest Equity Carrying Amount - - - - - - 210,944
  Partners Capital
    Limited Partners Capital Account
      Limited Partners Capital Account 4,281,841 4,955,649 6,002,592 6,999,830 6,322,307 6,523,929 6,670,365
      Accumulated Other Comprehensive Income Loss Net Of Tax 1,958 2,170 3,466 -20,864 -52,519 -62,887 -34,018
    Partners Capital 8,666,680 9,658,762 12,427,230 14,891,690 6,269,788 6,461,042 6,636,347
  Partners Capital Attributable To Noncontrolling Interest - - - - - - 3,253,148
  Non Controlling Interest In Partnerships 2,460,520 2,748,356 3,656,416 4,416,070 3,368,509 3,439,537 3,629,116
  Partners Capital Including Portion Attributable To Noncontrolling Interest - - - - 12,047,000 12,329,540 13,518,610
  Liabilities And Stockholders Equity 21,909,130 28,931,550 29,678,610 31,510,890 22,526,080 26,403,340 34,428,910

Peers - Investment Advice (6282)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 09257R101